SCHEMBL5087141

SCHEMBL5087141

COc1ccc2cc(C(=O)NC(=O)c3ccc(O)c(C(=O)O)c3)c(=O)oc2c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.49
▸ MAOB P27338 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.48
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA3 P07451 1/20 0.48
▸ CA4 P22748 1/20 0.48
▸ CA6 P23280 1/20 0.48
▸ CA5A P35218 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48
▸ CA5B Q9Y2D0 1/20 0.48
▸ MAPT P10636 3/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ GPR35 Q9HC97 3/20 0.43
▸ CNR2 P34972 3/20 0.43
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406666 0.92 MAOA (0.49) MAOAMAOBHSD17B10CA12CA1
SCHEMBL1406217 0.90 CNR2 (0.49) MAOAMAOBHSD17B10CA12CA1
SCHEMBL1406414 0.82 CA12 (0.68) MAOAMAOBHSD17B10CA12CA1
SCHEMBL1406194 0.82 GPR35 (0.48) HSD17B10CA12CA1CA2CA3
SCHEMBL1406450 0.81 GPR35 (0.49) MAOBHSD17B10CA12CA1CA2
SCHEMBL1406341 0.80 SLC16A3 (0.65) MAOBHSD17B10CA12CA1CA2
SCHEMBL1406469 0.79 GPR35 (0.43) MAOAMAOBCA12CA9MAPT
SCHEMBL1406864 0.78 MAPT (0.63) MAOAMAOBHSD17B10CA12CA1
SCHEMBL1406739 0.75 KDM4E (0.43) MAOAMAOBHSD17B10CA12CA1
SCHEMBL1406475 0.74 GPR35 (0.48) HSD17B10CA12CA1CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295053-B1 Novel 2H-chromen-2-one-3-carboxamides for medical uses INST MATERIA MEDICA CAMS (CN) 2016-10-19 — — EP disclosed
US-8338401-B2 Coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-12-25 — — US disclosed
WO-2008013928-A2 TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR BIOGEN IDEC MA INC. (US) 2008-01-31 — — WO disclosed
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSR, GLS, INSRR MAOA 4761/4885MAOB 4669/4885HSD17B10 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback